Experimental antibody offers hope for Tough-to-Treat leukemia patients
NCT ID NCT07384715
Summary
This is the first human trial of an experimental antibody called GEN3018 for adults with advanced blood cancers that have returned or resisted previous treatments. The main goals are to find a safe dose and see if the drug shows early signs of fighting the cancer. Up to 78 participants will receive the drug and be monitored closely for up to a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus Universitetshospital - Skejby
RECRUITINGAarhus, 8200, Denmark
-
Copenhagen Rigshospitalet
RECRUITINGCopenhagen, 2100, Denmark
Conditions
Explore the condition pages connected to this study.